The rise of copyright’s drug initially drove significant growth in the drug sector, creating a image of guaranteed returns. However, funding in companies solely reliant on flagship drugs like Sildenafil presents considerable challenges. Intellectual property end has caused alternative rivalry, decreasing market share and likely lowering projecte… Read More

The recent surge in funding into niche pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." While the promise for game-changing treatments and significant returns is undeniable, the linked risks are also significant. Many of t… Read More